RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Gracell Biotechnologies, a Suzhou immune cell gene therapy company, has completed an $85 million series B funding led by Temasek. Gracell is focused on developing best-in-class cellular medicines for cancer patients by addressing the complex manufacture and high cost of cellular gene therapeutics. With the new funds, it plans to start clinical trials with several of its next-gen immune cell gene therapy drug candidates. Lilly Asia Ventures, Kington Capital, King Star Capital and Chengdu Miaoji also participated in the funding.
Source: China Biotoday
